Glenmark Pharmaceuticals informs about media release

14 Jan 2022 Evaluate

Glenmark Pharmaceuticals has informed that it enclosed a media release on January 14,2021 titled ‘Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older’.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

1991.70 -1.00 (-0.05%)
29-Jan-2026 09:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1591.30
Dr. Reddys Lab 1194.30
Cipla 1308.60
Zydus Lifesciences 884.75
Lupin 2102.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×